Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody

Journal of Nuclear Medicine

Volumn 38, Issue 12, 1997, Pages 1951-1959

  Wong, Jeffrey Y C ^a   Thomas, Gail E ^b   Yamauchi, Dave ^b   Williams, Lawrence E ^b   Odom Maryon, Tamara L ^b   Liu, An ^b   Esteban, Jose M ^b   Neumaier, Michael ^b   Dresse, Stephanie ^b   Wu, Anna M ^b   Primus, F James ^b   Shively, John E ^b   Raubitschek, Andrew A ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

Carcinoembryonic antigen; Chimeric antibody; Indium 111; Radioimmunotherapy; Radiolabeled antibodies

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIBODY; PENTETATE INDIUM T84.66 IN 111; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; METASTASIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANIMALS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MICE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0031473623     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
2. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68:403-406.
3. Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 1988;48:6811-6818.
4. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
5. Esteban JM, Felder B, Ahn CA, Simpson JF, Battifora H, Shively JE. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575-1583.
6. Robbins PF, Eggensperger D, Qi CF, Schlom J. Definition of the expression of human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993;53:892-897.
7. Hansen HJ, Snyder LH, Miller E, et al. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. J Hum Pathol 1974;5:139-147.
8. 111indium anticarcinoembryonic antigen monoclonal antibody ZCE-025. Radiology 1987;164:617-621.
9. 111indium-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial. J Nucl Med 1993;34:1656-1661.
10. Goldenberg DM, Wlodkowski TJ, Sharkey RM, et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993;34:61-70.
11. Bischo-Delaloye A, Delaloye B. Diagnostic applications and therapeutic approaches with different preparations of anti-CEA antibodies. Int J Biol Markers 1992;7:193-197.
12. 131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1991;21: 1601-1605.
13. 111In-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1986;46:6494-6502.
14. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-885.
15. Courtenay-Luck LS, Epenetos AA, Moore R, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986;46:6489-6493.
16. Meredith RF, LoBuglio AF, Plott WE, et al. Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k17-1A monoclonal antibody. J Nucl Med 1991;32:1162-1168.
17. Pimm MV, Perkins AC, Armitage NC, Baldwin RW. The characteristics of blood-borne radiolabelled antibodies and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med 1985;26:1011-1023.
18. Khazaeli MB, Saleh MN, Liu TP, et al. Pharmacokinetics and immune response of 1311-chimeric mouse/human B72 3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991;51:5461-5466.
19. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14 18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-267.
20. LoBuglio AF, Wheeler RH, Tranf J, et al. Mouse-human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86: 4220-4224.
21. Goodman GE, Hellstrom I, Yelton DE, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993;36:267-273.
22. Buchegger F, Mach JP, Pelegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody in surgically treated colorectal carcinoma. J Nucl Med 1995;36:420-429.
23. Wagener C, Clark BR, Rickard KJ, Shively JE. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: determination of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay. J Immunol 1983;130: 2302-2307.
24. Wagener C, Yang YHJ, Crawford FG, Shively JE. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: a systematic approach for the determination of epitope specificities of monoclonal antibodies. J Immunol 1983;130:2308-2315.
25. Hefta LJ, Wu AM, Neumaier M, Shively JE. Measuring antibody affinity using biosensors. In: Chiswell D, MacCafferty J, Hoogenboom H, eds. Antibody engineering: a practical approach. London: Oxford Press; 1995:99-117.
26. 111indium. Nucl Med Biol 1990;17:247-254.
27. Neumaier M, Shively L, Chen FS, et al. Cloning of the genes for T84 66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, expression of chimeric human/mouse T84 66 genes in myeloma and Chinese hamster ovary cells. Cancer Res 1990;50:2128-2134.
28. 90yttrium radiolabeled anti-CEA chimeric T84 66 in a Phase I radioimmunotherapy trial. Cancer Res 1995;55(suppl):5929s-5934s.
29. Williams LE, Primus FJ, Wong JYC, et al. Biodistribution of an In-111 or Y-90 labeled chimeric anti-CEA monoclonal antibody (cT84 66) following its large scale production in a bioreactor. Tumor Targeting 1996;2:116-124.
30. Galen RS, Fink DJ. Probabilistic approaches to clinical decision support. In: Computer aids to clinical decisions, Vol. 2. Boca Raton, FL: CRC Press, Inc; 1982:7-10.
31. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prog Biomed 1979;9:115-134.
32. Odom-Maryon TL, Chai A, Williams LE, et al. Pharmacokinetics and modeling of cT84.66 chimeric anti-CEA antibody in humans. J Nucl Med; in press.
33. Loevinger R, Berman M. MIRD Pamphlet No. 1, Revised. New York: Society of Nuclear Medicine; 1976.
34. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl Med 1996;37:538-546.
35. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213-233.
36. Buras RB, Williams LE, Beatty BG, Wong JYC, Beatty JD, Wanek PM. A method including edge effects for the estimation of radioimmunotherapy absorbed doses in the tumor xenograft model. Med Phys 1994;21:287-292.
37. Corbisiero RM, Yamauchi DM, Williams LE, et al. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res 1991;51:5704-5711.
38. Pan YZ, Lamki LM, Haynie TP, et al. Improved rumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 1988;8:1220-1230.
39. Patt YZ, Lamki LM, Shanken J, et al. Imaging with indium-111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 1990;8:1246-1254.
40. Yu B, Carrasquilo J, Milenic D, et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996;6:1798-1809.
41. 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. Cancer Res 1989;49:1587-1594.
42. 90Y activity needed to achieve certain tumor radiation doses in colorectal cancer patients. Cancer Res 1990;50(suppl):1029s-1030s.
43. Weiden PL, Breitz HB, Seiler CA, et al. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J Nucl Med 1993;34:2111-2119.
44. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: a mathematical model. J Nucl Med 1988;29:103-109.
45. Kuhn JA, Corbisiero RM, Buras RR, et al. Intraoperative gamma detection probe with presurgical antibody imaging in colorectal cancer. Arch Surg 1991;126:1398-1403.
46. Epenetos AA. Antibody guided lymphangiography in the staging of cervical cancer. Br J Cancer 1985;51:805-808.
47. 125I-radiolabeled monoclonal antibody CC49. Cancer 1996;77:613-620.